ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
Vivoryon Therapeut

Vivoryon Therapeut (VVY)

2.05
0.02
(0.99%)
終了 11月19日 1:30AM

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

主要統計と詳細

通貨
2.05
買値
2.00
売値
2.10
出来高
85,189
2.005 日の範囲 2.075
0.41 52 週間の範囲 9.93
時価総額
前日終値
2.03
始値
2.005
最終取引時間
財務取引量
-
VWAP
-
平均取引量 (3 か月)
186,544
発行済株式数
0.00
配当利回り
-
PER
0.00
1 株当たり利益 (EPS)
-
歳入
-3.62M
純利益
-28.34M

Vivoryon Therapeut について

セクター
Biological Pds,ex Diagnstics
業界
Biological Pds,ex Diagnstics
ウェブサイト
本社
Halle, Deu
設立
-
Vivoryon Therapeut is listed in the Biological Pds,ex Diagnstics sector of the ユーロネクスト with ticker VVY. The last closing price for Vivoryon Therapeut was 2.03 €. Over the last year, Vivoryon Therapeut shares have traded in a share price range of 0.41 € to 9.93 €.

Vivoryon Therapeut currently has 0 shares in issue.

VVY 最新ニュース

Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of Varoglutamstat on Kidney Function at ASN Kidney Week 2024

Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of Varoglutamstat on Kidney Function at ASN Kidney Week 2024 Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of...

Vivoryon Therapeutics N.V. Announces Late-breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024

Vivoryon Therapeutics N.V. Announces Late-breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024 Halle (Saale) / Munich, Germany, October 11, 2024 – Vivoryon...

Vivoryon Therapeutics N.V. Shares Highlights from Virtual Kidney Disease KOL Event

Vivoryon Therapeutics N.V. Shares Highlights from Virtual Kidney Disease KOL Event Halle (Saale) / Munich, Germany, October 1, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY;...

Vivoryon Therapeutics N.V. Reports H1 2024 Progress Marked by Compelling Kidney Function Data and Execution of Strategy to Advance Varoglutamstat in Kidney Disease

Vivoryon Therapeutics N.V. Reports H1 2024 Progress Marked by Compelling Kidney Function Data and Execution of Strategy to Advance Varoglutamstat in Kidney Disease Vivoryon Therapeutics N.V...

Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and Change to Articles of Association

Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and Change to Articles of Association Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and...

Vivoryon Therapeutics N.V. to Report Half Year 2024 Financial Results on September 12, and to Host KOL Event on September 30, 2024

Vivoryon Therapeutics N.V. to Report Half Year 2024 Financial Results on September 12, and to Host KOL Event on September 30, 2024 Vivoryon Therapeutics N.V. to Report Half Year 2024 Financial...

Vivoryon Therapeutics N.V. Announces New Data Showing Unique Treatment Effects of Varoglutamstat on Kidney Function in Patients with Diabetes and Outlines Proposed Clinical Development Plan in Diabetic Kidney Disease

Vivoryon Therapeutics N.V. Announces New Data Showing Unique Treatment Effects of Varoglutamstat on Kidney Function in Patients with Diabetes and Outlines Proposed Clinical Development Plan in...

Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on Progress in Kidney Disease

Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on Progress in Kidney Disease Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on...

Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on Progress in Kidney Disease

Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on Progress in Kidney Disease Halle (Saale) / Munich, Germany, July 9, 2024 - Vivoryon Therapeutics N.V. (Euronext...

Vivoryon Therapeutics N.V. Reports Outcome of 2024 Annual General Meeting

Vivoryon Therapeutics N.V. Reports Outcome of 2024 Annual General Meeting Vivoryon Therapeutics N.V. Reports Outcome of 2024 Annual General Meeting Halle (Saale) / Munich, Germany, June 21...

期間 †前日比前日比 %始値高値安値平均出来高VWAP
1-0.155-7.029478458052.2052.242.005734522.0944024DE
4-0.34-14.22594142262.392.592.0051335942.32869083DE
12-0.17-7.657657657662.222.9951.8241865442.3276004DE
261.248155.6109725690.8026.30.786322622.4738679DE
52-5.75-73.71794871797.89.930.415406432.06117631DE
156-16.7-89.066666666718.7520.6350.412205243.93028214DE
260-3.15-60.57692307695.223.250.411707885.17776562DE

ムーバー

すべて表示
  • 出来高
  • 値上がり率
  • 値下がり率
銘柄コード株価出来高
MHMMyHotelMatch
0.598 €
(71.84%)
72.21k
CNVCnova NV
1.125 €
(60.71%)
14.78k
EMGDSEuromedis DS
0.015 €
(36.36%)
11.96k
MLNMAMiguet Et Associes
0.0995 €
(24.38%)
650
EBUSEbusco Holding NV
1.51 €
(19.27%)
944.29k
EBUSREbusco
0.0003 €
(-99.81%)
6.18M
MLONEBody One
0.24 €
(-25.00%)
3.18k
ALSPWSpineway
0.1066 €
(-18.00%)
2.22M
HYLHyloris Pharmaceuticals SA
3.30 €
(-17.50%)
51k
ALVERVergnet
0.0049 €
(-15.52%)
9.6M
ALNEVNeovacs
0.0002 €
(0.00%)
43.54M
BCPBanco Comercial Portugues SA
0.4476 €
(0.65%)
24.98M
ALHPIHopium SA
0.0098 €
(-2.00%)
19.79M
ALCYBCybergun
0.0001 €
(0.00%)
12.96M
ALVERVergnet
0.0049 €
(-15.52%)
9.6M

最近閲覧した銘柄

Delayed Upgrade Clock